Atsena Therapeutics is set to proceed with the Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 in patients with XLRS.

The post Atsena secures DMC approval for LIGHTHOUSE trial appeared first on Clinical Trials Arena.